Trans-kingdom conservation of mechanism between bacterial actifensin and eukaryotic defensins

TL;DR

This study shows that a bacterial peptide, actifensin, shares similarities with eukaryotic defensins and could be a promising therapy against drug-resistant bacteria.

Contribution

The study reveals a conserved trans-kingdom mechanism between bacterial actifensin and eukaryotic defensins.

Findings

Actifensin inhibits peptidoglycan synthesis by binding lipid II and lipid I.

Actifensin does not cause membrane disruption or toxicity in human cells.

Actifensin belongs to a conserved trans-kingdom defensin subfamily with a GXGCP motif.

Abstract

Antimicrobial peptides are defense molecules found across all domains of life holding promise for developing therapies against drug-resistant pathogens. Actifensin, from Actinomyces ruminicola DPC7226, exhibits potent activity against gram-positive bacteria and shares structural similarities with eukaryotic defensins. This study characterized actifensin’s mechanism of action and therapeutic potential. The findings revealed that actifensin inhibits peptidoglycan synthesis by binding lipid II (Kd = 30 ± 20 nM). Unlike defensins, it also binds lipid I (Kd = 24 ± 27 nM) without significant difference, suggesting the N-acetyl glucosamine moiety of lipid II is not required for complexation. Membrane disruption was not observed with DiSC3(5) fluorescence, or synthetic unilamellar liposomes, indicating indirect cell death via cell wall weakening, visualised by phase contrast microscopy. Actifensin showed no haemolytic activity or toxicity up to 128 µg/ml in human erythrocytes and Hep G2 cells. The peptide was not immunogenic, demonstrating no induction of LDH release in PBMCs or any effect on TLR-mediated signalling. Structural motif analysis identified actifensin as part of a conserved trans-kingdom defensin subfamily, GXGCP, distinct from XTCD peptides in more recently evolved arthropods. These findings emphasise the conserved structure-function relationship of antimicrobials across kingdoms, suggesting a shared evolutionary history of defensins and highlight the therapeutic potential for them or their variants.

Figures